We use cookies to improve your experience, analyze site usage, and show relevant ads. Go to our Privacy Policy for details.
The call presented strong commercial momentum and meaningful pipeline and BD progress: solid Q1 sales growth (~42.9% YoY), an upward revision to full-year guidance, funded R&D investments, prioritized near-term regulatory catalysts (including a PDUFA on September 26, 2026), and a plan to scale the commercial team. These positives are tempered by a very large, one-time operating expense tied to the Bluejay acquisition that drove an unusually high quarterly operating charge ($761M of $949M), minimal Q1 operating cash flow (~$2M), elevated R&D spend, and remaining data and market-size uncertainties for some pipeline assets (e.g., FOP patient counts and certain subgroup signals in hepatitis delta). Management expects operating cash flow positivity next year and GAAP profitability by 2028, indicating confidence in the business model despite near-term accounting and investment-driven headwinds.
Mirum raised full-year 2026 net product sales guidance to $660–$680 million after reporting Q1 net product sales of about $160 million (including Livmarli/Lemarli sales of $84 million U.S. and $30 million international, and $46 million from the bile acid medicines), supported by a Q1 cash contribution margin in the mid‑50% range and cash flow from operations of about $2 million; cash, cash equivalents and investments were $421 million at March 31 (vs. $391 million at year‑start). Management expects R&D spending to step up in 2026 (Q1 R&D was $98 million, including $21 million for berlovitag) but says this investment is fully funded; total operating expense in Q1 was $949 million (including $761 million related to the Bluejay acquisition), with SG&A of $96 million, cost of sales of $29 million, and non‑cash items of $64 million (including $35 million of stock‑based comp). The Bluejay acquisition had $253 million net cash outflow in Q1 offset by $260 million of financing proceeds; Mirum paid a $16 million upfront fee to Incyte for zolergosertib (with a $25 million FDA approval milestone and mid‑ to high‑single‑digit royalties), expects the PDUFA date of September 26, 2026 and a potential year‑end launch if approved, plans to expand the U.S. liver field team from ~20 to ~60 to reach >4,000 HCPs, expects to be operating cash‑flow positive next year, and projects GAAP profitability around 2028.
Q1 net product sales of ~$160 million versus $112 million in Q1 last year, a ~42.9% increase year-over-year. Company raised full-year 2026 net product sales guidance to $660 million–$680 million, driven primarily by strong PFIC uptake and better-than-expected international performance.
Cash, cash equivalents, and investments of $421 million as of March 31, 2026, up from $391 million at the beginning of the year (a ~7.7% increase). Management states planned R&D step-ups in 2026 are fully funded.
Cash contribution margin from commercial business in the mid-50% range in Q1, indicating solid unit economics from marketed products.
Positive clinical signals: VISTA (vilixibat) in PSC showed significant improvement in pruritus; AZURE-1 Phase 2b in hepatitis delta produced supportive results. Both programs represent opportunities to expand rare liver business from pediatric to larger adult populations and will have late-breaking presentations at EASL.
Licensing of zolergosertib (from Incyte) for FOP: NDA accepted with priority review, PDUFA date of September 26, 2026, and potential launch by year-end if approved. Upfront fee $16 million; $25 million milestone upon U.S. FDA approval; royalties mid- to high-single-digits. Company estimates peak global sales of $200M+ for the asset.
Planned U.S. liver field commercial expansion from ~20 to ~60 sales representatives, increasing reach from ~1,500 to over 4,000 liver health care providers to support adult liver indications (PFIC adult patients, PSC, hepatitis delta) and international expansion.
Bluejay acquisition net cash outflow of $253 million was offset by net financing proceeds of $260 million, demonstrating ability to execute transformational transactions while maintaining liquidity; company expects operating cash flow positive next year (2027).
Good afternoon, and welcome to Mirum Pharmaceuticals, Inc. First Quarter 2026 earnings conference call. My name is Tracy, and I will be your operator today. All lines are currently in a listen-only mode, and there will be an opportunity for Q&A after management's prepared remarks. I would now like to hand the conference over to Andrew McKibben, SVP of Strategic Finance and Investor Relations. Please go ahead.
Thank you, Tracy, and good afternoon, everyone. I would like to welcome you to Mirum Pharmaceuticals, Inc. first quarter 2026 earnings conference call. For our prepared remarks, I am joined today by our Chief Executive Officer, Christopher Peetz, our President and Chief Operating Officer, Peter Radovich, and Eric H. Bjerkholt, our Chief Financial Officer. Our Chief Medical Officer, Joanne M. Quan, will be joining us for Q&A. Earlier this afternoon, Mirum Pharmaceuticals, Inc.
issued a press release reporting our first quarter 2026 financial results. Copies of the press release and our SEC filings are available in the Investors section of our website. Before we start, I would like to remind you that during the course of this conference call, we will be making certain forward-looking statements based on management's current expectations, including statements regarding Mirum Pharmaceuticals, Inc.'s programs and market opportunities for its approved medicines and product candidates and financial guidance. These statements represent our judgment and knowledge of events as of today and inherently involve risks and uncertainties that may cause actual results to differ materia...